Latest Period
Q2 2026
Security Snapshot
Black Diamond Therapeutics, Inc. - Common Stock (BDTX) Institutional Ownership
CUSIP: 09203E105
13F Institutional Holders and Ownership History from Q1 2020 to Q2 2026
Institutions Reporting
95
Shares (Excl. Options)
35,049,068
Price
$1.85
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- BDTX on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 35,049,068
- Total 13F value
- $64,884,920
- Portfolio coverage rank
- 0%
- Share change
- -3,453,773
- Value change
- -$7,585,046
- Number of holders
- 95
- Shares outstanding
- 57,292,388
- SEC-reported price per share
- $1.87
- Insider filing price
- $1.87
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- BDTX - Black Diamond Therapeutics, Inc. - Common Stock is tracked under CUSIP 09203E105.
- 95 institutions reported positions in Q2 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 102 to 95 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $82,030,473 to $64,884,920.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 95 institutions filings for Q2 2026.
Security key
09203E105
Latest holder period
Q2 2026
13F holders
95
13D/G owners
4
CIK / CUSIP context first
Open Q2 2026 holders
BDTX full holder history
Black Diamond Therapeutics, Inc. SEC filings
Black Diamond Therapeutics, Inc. company facts
Black Diamond Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 09203E105:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
BDTX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 7% | $9,103,737 | 4,028,202 | T. Rowe Price Investment Management, Inc. | 30 Jun 2026 | |||
| BlackRock, Inc. | 6.7% | +44% | $7,101,392 | +$2,432,878 | 3,838,590 | +52% | BlackRock, Inc. | 30 Jun 2026 |
| BB BIOTECH AG | 4.8% | -69% | $4,373,675 | -$9,254,867 | 2,733,547 | -68% | BB Biotech AG | 19 Mar 2025 |
| Vestal Point Capital, LP | 1.5% | $2,166,300 | 870,000 | Vestal Point Capital, LP | 31 Dec 2025 |
As of 30 Jun 2026, 95 institutional investors reported holding 35,049,068 shares of Black Diamond Therapeutics, Inc. - Common Stock (BDTX). This represents 61% of the company’s total 57,292,388 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
55%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| NEA Management Company, LLC | 7.8% | 4,448,757 | 0% | 0.52% | $8,230,200 |
| T. Rowe Price Investment Management, Inc. | 7% | 4,028,202 | -62% | 0% | $7,453,000 |
| BlackRock, Inc. | 6.8% | 3,917,088 | +254% | 0% | $7,246,613 |
| ACADIAN ASSET MANAGEMENT LLC | 4.1% | 2,348,651 | 0% | 0.01% | $4,338,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.7% | 2,125,270 | +15% | 0% | $3,931,750 |
| RENAISSANCE TECHNOLOGIES LLC | 3.4% | 1,962,394 | +19% | 0% | $3,630,429 |
| Defilade Capital Management, L.P. | 2.9% | 1,674,999 | 0.41% | $3,098,748 | |
| DIMENSIONAL FUND ADVISORS LP | 2.4% | 1,365,384 | +4.9% | 0% | $2,525,486 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.1% | 1,218,171 | +127% | 0% | $2,254,419 |
| Connor, Clark & Lunn Investment Management Ltd. | 1.9% | 1,092,885 | +3.3% | 0% | $2,021,837 |
| AWM Investment Company, Inc. | 1.7% | 1,000,000 | +90% | 0.16% | $1,850,000 |
| MARSHALL WACE, LLP | 1.6% | 896,602 | +7.2% | 0% | $1,658,714 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 1.4% | 791,434 | +9.4% | 0.03% | $1,464,153 |
| FMR LLC | 1.1% | 643,668 | +3.2% | 0% | $1,190,786 |
| Balyasny Asset Management L.P. | 0.95% | 542,172 | +6.1% | 0% | $1,003,018 |
| STATE STREET CORP | 0.92% | 525,013 | +146% | 0% | $971,274 |
| BANK OF AMERICA CORP /DE/ | 0.72% | 413,516 | +262% | 0% | $765,004 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.71% | 407,074 | +337% | 0% | $753,087 |
| NORTHERN TRUST CORP | 0.64% | 365,394 | -21% | 0% | $675,979 |
| Bank of New York Mellon Corp | 0.56% | 318,762 | +69% | 0% | $589,710 |
| VANGUARD FIDUCIARY TRUST CO | 0.54% | 309,853 | +19% | 0% | $573,228 |
| PANAGORA ASSET MANAGEMENT INC | 0.52% | 295,172 | 0% | $546,068 | |
| JANE STREET GROUP, LLC | 0.51% | 289,712 | +206% | 0% | $535,967 |
| O'SHAUGHNESSY ASSET MANAGEMENT, LLC | 0.5% | 288,871 | +59% | 0% | $534,411 |
| GOLDMAN SACHS GROUP INC | 0.5% | 288,780 | -58% | 0% | $534,243 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
26
Latest
Q2 2026
Rows shown
1-25 of 26
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 35,049,068 | $64,884,920 | -$7,585,046 | $1.85 | 95 |
| 2026 Q1 | 38,514,397 | $82,030,473 | +$540,526 | $2.13 | 102 |
| 2025 Q4 | 37,853,431 | $92,001,922 | -$6,001,452 | $2.43 | 103 |
| 2025 Q3 | 38,780,810 | $146,973,938 | +$5,639,493 | $3.79 | 89 |
| 2025 Q2 | 38,616,493 | $95,766,554 | -$4,378,949 | $2.48 | 92 |
| 2025 Q1 | 40,656,241 | $63,017,852 | -$11,756,469 | $1.55 | 83 |
| 2024 Q4 | 47,903,925 | $102,516,125 | -$13,785,684 | $2.14 | 85 |
| 2024 Q3 | 48,717,118 | $211,892,256 | +$1,570,817 | $4.35 | 95 |
| 2024 Q2 | 46,760,739 | $217,913,327 | +$31,657,196 | $4.66 | 88 |
| 2024 Q1 | 39,430,252 | $199,910,697 | +$10,671,909 | $5.07 | 86 |
| 2023 Q4 | 38,119,952 | $107,120,051 | +$4,413,540 | $2.81 | 73 |
| 2023 Q3 | 37,180,210 | $106,709,201 | -$21,943,325 | $2.87 | 71 |
| 2023 Q2 | 41,421,828 | $209,176,335 | +$105,453,106 | $5.05 | 72 |
| 2023 Q1 | 21,491,972 | $40,617,428 | +$846,555 | $1.89 | 47 |
| 2022 Q4 | 21,053,167 | $37,894,305 | -$721,593 | $1.80 | 56 |
| 2022 Q3 | 21,487,475 | $36,340,473 | -$284,945 | $1.69 | 57 |
| 2022 Q2 | 21,498,645 | $52,895,689 | -$3,549,739 | $2.46 | 56 |
| 2022 Q1 | 22,887,182 | $64,088,307 | -$2,429,770 | $2.77 | 69 |
| 2021 Q4 | 23,198,177 | $123,630,624 | -$12,989,218 | $5.33 | 83 |
| 2021 Q3 | 24,374,413 | $206,301,397 | -$11,175,534 | $8.46 | 89 |
| 2021 Q2 | 25,397,669 | $309,589,838 | -$81,437,251 | $12.19 | 97 |
| 2021 Q1 | 29,083,953 | $705,520,847 | -$7,557,586 | $24.26 | 109 |
| 2020 Q4 | 28,616,097 | $917,170,806 | +$140,401,559 | $32.05 | 109 |
| 2020 Q3 | 23,764,080 | $718,480,421 | +$753,590 | $30.23 | 88 |
| 2020 Q2 | 22,835,597 | $959,367,654 | +$39,864,306 | $42.16 | 79 |